GLPG
- Galapagos NV
()
Overview
Company Summary
Galapagos NV (GLPG) is a global biotechnology company engaged in the discovery, development, and commercialization of innovative medicines. Founded in Belgium in 1999, Galapagos focuses on the research and development of small molecule and antibody-based therapies to address unmet medical needs.
Galapagos operates through a unique R&D-driven business model that combines its proprietary target discovery platform with strategic partnerships and collaborations with pharmaceutical companies. The company's platform is built on the understanding of human disease biology and genetics, allowing them to identify novel disease targets and develop therapeutic candidates.
Galapagos primarily focuses on developing treatments for inflammatory diseases, fibrosis, and other serious diseases with limited or no treatment options available. Their pipeline includes a range of drug candidates in different stages of development, targeting diseases like rheumatoid arthritis, ulcerative colitis, idiopathic pulmonary fibrosis, and various other diseases.
In addition to its internal development programs, Galapagos has established strategic partnerships with several pharmaceutical companies, including Gilead Sciences. These collaborations provide Galapagos with financial support, access to expertise, and potential commercialization opportunities.
Overall, Galapagos NV is dedicated to advancing the field of biotechnology by discovering and developing innovative medicines that can significantly impact patients' lives. Through its unique approach and strong collaborations, the company aims to address the unmet medical needs of patients worldwide.